Gerhard Koenig, Arkuda CEO
Atlas-backed neurology player Arkuda reemerges from the grindstone with a lead progranulin drug approaching the clinic
In the bustling biotech space, a couple years can feel like an eternity — but for an Atlas Venture-backed neurology player with a novel spin on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
